Testing a new medication for veterans with PTSD
Official title: Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment ofVeterans with Posttraumatic Stress Disorder (PTSD)
Funded at Veterans Affairs Med Ctr San Francisco · NIH-11044036 · Data updated 2026-11-12
This study is looking at how well a new medication called CORT108297 can help veterans with posttraumatic stress disorder (PTSD) by improving their body's stress response, and participants will take the medication and share how they're feeling throughout the trial.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Affairs Med Ctr San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| NIH project number | 5I01CX001917-04 |
| Project ID | NIH-11044036 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are veterans diagnosed with chronic PTSD who do not have a history of traumatic brain injury.
✕Less likely to help
Patients with PTSD who have a history of traumatic brain injury may not benefit from this research.
What this research studies
This research investigates the effectiveness of a new glucocorticoid receptor antagonist, CORT108297, in treating veterans suffering from posttraumatic stress disorder (PTSD). The study aims to recalibrate the body's stress response system by targeting the hypothalamus-pituitary-adrenal (HPA) axis, which is often dysregulated in PTSD. Participants will receive the medication and be monitored for improvements in their symptoms over the course of the trial. The approach builds on previous findings that showed promise with similar medications.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment option for veterans with PTSD.
How similar studies have gone: Previous trials with glucocorticoid receptor antagonists have shown clinical benefits, indicating potential for success with this new approach.
Where this research is happening
-
Veterans Affairs Med Ctr San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Neylan, Thomas C — Veterans Affairs Med Ctr San Francisco
- Study coordinator: Neylan, Thomas C
Related research
Other NIH-funded projects on the same topics.
-
Computationally mapping PTSD to better diagnosis and personalized care
A research project uses computer tools to find brain-based patterns that could help diagnose PTSD more clearly and tailor treatments for Veterans and others with PTSD.
-
Targeted glucocorticoid-blocking medicine for Veterans with PTSD
Veterans with PTSD will receive a selective glucocorticoid receptor blocker called CORT108297 to help reduce stress-related PTSD symptoms.
-
Creating new ways to diagnose and treat PTSD
This study is looking to make it easier to diagnose and treat PTSD by using smart computer tools to better understand the different symptoms people experience, which could lead to more personalized care for those affected.
-
Transcutaneous Vagal Nerve Stimulation for PTSD in Veterans
A non-invasive device gently stimulates the vagus nerve to help reduce PTSD symptoms in veterans.
-
Understanding how PTSD affects self-control and brain function
Researchers are studying how PTSD changes the brain’s control over thoughts and actions, and how this might affect Veterans’ daily lives and responses to treatment.
-
Ketamine to boost fear extinction and memory on PTSD patients
A study testing whether ketamine can help people with PTSD better relearn and forget fear when given in a guided treatment plan.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.